Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 31Lung Neoplasms 25Carcinoma, Non-Small-Cell Lung 20Breast Neoplasms 19Lymphoma 18Multiple Myeloma 17Glioblastoma 17Prostatic Neoplasms 16Urinary Bladder Neoplasms 15Glioma 15Carcinoma, Renal Cell 15Melanoma 13Squamous Cell Carcinoma of Head and Neck 12Sarcoma 12Ovarian Neoplasms 12Colorectal Neoplasms 12Central Nervous System Neoplasms 12Triple Negative Breast Neoplasms 11Mouth Neoplasms 11Pancreatic Neoplasms 10Oropharyngeal Neoplasms 10Neuroblastoma 10Medulloblastoma 10Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Laryngeal Neoplasms 10Carcinoma, Transitional Cell 10Thyroid Neoplasms 9Fallopian Tube Neoplasms 9Ependymoma 9

Interventions

cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Urachal adenocarcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡